Supplemental Table 1 Details of References by Cluster in VOSviewer

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| id | label | Weight<Citations> | Weight<Co-citations> | Cluster |
| 636 | al-hajj m, 2003, p natl acad sci usa, v100, p3983, doi 10.1073/pnas.0530291100 | 56 | 329 | 3 |
| 1547 | atchley dp, 2008, j clin oncol, v26, p4282, doi 10.1200/jco.2008.16.6231 | 58 | 601 | 2 |
| 2340 | bauer kr, 2007, cancer, v109, p1721, doi 10.1002/cncr.22618 | 298 | 2958 | 1 |
| 2821 | bertucci f, 2008, int j cancer, v123, p236, doi 10.1002/ijc.23518 | 84 | 1324 | 1 |
| 3796 | brenton jd, 2005, j clin oncol, v23, p7350, doi 10.1200/jco.2005.03.3845 | 62 | 633 | 1 |
| 4013 | bryant he, 2005, nature, v434, p913, doi 10.1038/nature03443 | 50 | 679 | 2 |
| 4209 | burstein hj, 2008, j clin oncol, v26, p1810, doi 10.1200/jco.2007.14.5375 | 56 | 988 | 2 |
| 4302 | byrski t, 2010, j clin oncol, v28, p375, doi 10.1200/jco.2008.20.7019 | 58 | 748 | 2 |
| 4621 | carey l, 2010, nat rev clin oncol, v7, p683, doi 10.1038/nrclinonc.2010.154 | 96 | 593 | 3 |
| 4633 | carey la, 2006, jama-j am med assoc, v295, p2492, doi 10.1001/jama.295.21.2492 | 301 | 2996 | 1 |
| 4636 | carey la, 2007, clin cancer res, v13, p2329, doi 10.1158/1078-0432.ccr-06-1109 | 278 | 2974 | 1 |
| 4658 | carey la, 2012, j clin oncol, v30, p2615, doi 10.1200/jco.2010.34.5579 | 58 | 569 | 3 |
| 5279 | cheang mcu, 2008, clin cancer res, v14, p1368, doi 10.1158/1078-0432.ccr-07-1658 | 155 | 1935 | 1 |
| 6187 | cleator s, 2007, lancet oncol, v8, p235, doi 10.1016/s1470-2045(07)70074-8 | 149 | 1241 | 1 |
| 6494 | corkery b, 2009, ann oncol, v20, p862, doi 10.1093/annonc/mdn710 | 59 | 632 | 2 |
| 6879 | curtis c, 2012, nature, v486, p346, doi 10.1038/nature10983 | 58 | 385 | 3 |
| 7700 | dent r, 2007, clin cancer res, v13, p4429, doi 10.1158/1078-0432.ccr-06-3045 | 512 | 4455 | 3 |
| 7706 | dent r, 2009, breast cancer res tr, v115, p423, doi 10.1007/s10549-008-0086-2 | 78 | 887 | 2 |
| 8937 | elston cw, 1991, histopathology, v19, p403, doi 10.1111/j.1365-2559.1991.tb00229.x | 66 | 493 | 3 |
| 9429 | farmer h, 2005, nature, v434, p917, doi 10.1038/nature03445 | 105 | 1486 | 2 |
| 9756 | finn rs, 2007, breast cancer res tr, v105, p319, doi 10.1007/s10549-006-9463-x | 65 | 1030 | 2 |
| 9958 | fong pc, 2009, new engl j med, v361, p123, doi 10.1056/nejmoa0900212 | 90 | 1168 | 2 |
| 10053 | foulkes wd, 2003, j natl cancer i, v95, p1482, doi 10.1093/jnci/djg050 | 119 | 1493 | 2 |
| 10071 | foulkes wd, 2010, new engl j med, v363, p1938, doi 10.1056/nejmra1001389 | 258 | 1421 | 3 |
| 10385 | fulford lg, 2007, breast cancer res, v9, doi 10.1186/bcr1636 | 59 | 852 | 1 |
| 11301 | gluz o, 2009, ann oncol, v20, p1913, doi 10.1093/annonc/mdp492 | 95 | 721 | 1 |
| 11518 | gonzalez-angulo am, 2011, clin cancer res, v17, p1082, doi 10.1158/1078-0432.ccr-10-2560 | 65 | 600 | 2 |
| 12442 | haffty bg, 2006, j clin oncol, v24, p5652, doi 10.1200/jco.2006.06.5664 | 201 | 2064 | 1 |
| 12627 | hammond meh, 2010, j clin oncol, v28, p2784, doi 10.1200/jco.2009.25.6529 | 75 | 653 | 3 |
| 14096 | hu zy, 2006, bmc genomics, v7, doi 10.1186/1471-2164-7-96 | 55 | 811 | 1 |
| 14264 | hudis ca, 2011, oncologist, v16, p1, doi 10.1634/theoncologist.2011-s1-01 | 72 | 395 | 3 |
| 14278 | hugh j, 2009, j clin oncol, v27, p1168, doi 10.1200/jco.2008.18.1024 | 57 | 799 | 2 |
| 14697 | irvin wj, 2008, eur j cancer, v44, p2799, doi 10.1016/j.ejca.2008.09.034 | 53 | 541 | 1 |
| 16144 | kassam f, 2009, clin breast cancer, v9, p29, doi 10.3816/cbc.2009.n.005 | 63 | 567 | 2 |
| 16412 | kennedy rd, 2004, j natl cancer i, v96, p1659, doi 10.1093/jnci/djh312 | 54 | 733 | 2 |
| 16713 | kim mj, 2006, hum pathol, v37, p1217, doi 10.1016/j.humpath.2006.04.015 | 50 | 614 | 1 |
| 17092 | koboldt dc, 2012, nature, v490, p61, doi 10.1038/nature11412 | 148 | 948 | 3 |
| 17503 | kreike b, 2007, breast cancer res, v9, doi 10.1186/bcr1771 | 102 | 1475 | 1 |
| 18041 | lakhani sr, 2005, clin cancer res, v11, p5175, doi 10.1158/1078-0432.ccr-04-2424 | 65 | 986 | 2 |
| 18693 | lehmann bd, 2011, j clin invest, v121, p2750, doi 10.1172/jci45014 | 261 | 1731 | 3 |
| 19360 | liedtke c, 2008, j clin oncol, v26, p1275, doi 10.1200/jco.2007.14.4147 | 309 | 3016 | 2 |
| 19496 | lin nu, 2008, cancer, v113, p2638, doi 10.1002/cncr.23930 | 64 | 786 | 2 |
| 19979 | livasy ca, 2006, modern pathol, v19, p264, doi 10.1038/modpathol.3800528 | 134 | 1904 | 1 |
| 20442 | lund mj, 2009, breast cancer res tr, v113, p357, doi 10.1007/s10549-008-9926-3 | 55 | 643 | 1 |
| 22124 | metzger o, 2012, j clin oncol, v30, p1879, doi 10.1200/jco.2011.38.2010 | 53 | 291 | 3 |
| 22311 | miller k, 2007, new engl j med, v357, p2666, doi 10.1056/nejmoa072113 | 98 | 1428 | 2 |
| 22353 | millikan rc, 2008, breast cancer res tr, v109, p123, doi 10.1007/s10549-007-9632-6 | 84 | 967 | 1 |
| 22924 | morris gj, 2007, cancer, v110, p876, doi 10.1002/cncr.22836 | 88 | 1228 | 1 |
| 23823 | neve rm, 2006, cancer cell, v10, p515, doi 10.1016/j.ccr.2006.10.008 | 97 | 577 | 3 |
| 23982 | nielsen to, 2004, clin cancer res, v10, p5367, doi 10.1158/1078-0432.ccr-04-0220 | 320 | 3511 | 1 |
| 24366 | o'shaughnessy j, 2011, new engl j med, v364, p205, doi 10.1056/nejmoa1011418 | 90 | 1008 | 2 |
| 25390 | parker js, 2009, j clin oncol, v27, p1160, doi 10.1200/jco.2008.18.1370 | 75 | 873 | 3 |
| 25812 | perou cm, 2000, nature, v406, p747, doi 10.1038/35021093 | 458 | 4245 | 3 |
| 26450 | prat a, 2010, breast cancer res, v12, doi 10.1186/bcr2635 | 79 | 745 | 3 |
| 26904 | rakha ea, 2007, cancer-am cancer soc, v109, p25, doi 10.1002/cncr.22381 | 224 | 2427 | 1 |
| 26914 | rakha ea, 2008, j clin oncol, v26, p2568, doi 10.1200/jco.2007.13.1748 | 111 | 1104 | 1 |
| 26921 | rakha ea, 2009, clin cancer res, v15, p2302, doi 10.1158/1078-0432.ccr-08-2132 | 85 | 1176 | 1 |
| 26923 | rakha ea, 2009, pathology, v41, p40, doi 10.1080/00313020802563510 | 55 | 599 | 3 |
| 27319 | reis-filho js, 2008, histopathology, v52, p108, doi 10.1111/j.1365-2559.2007.02889.x | 166 | 1742 | 1 |
| 27854 | rodriguez-pinilla sm, 2006, clin cancer res, v12, p1533, doi 10.1158/1078-0432.ccr-05-2281 | 54 | 748 | 1 |
| 28128 | rouzier r, 2005, clin cancer res, v11, p5678, doi 10.1158/1078-0432.ccr-04-2421 | 149 | 2069 | 1 |
| 29191 | schneider bp, 2008, clin cancer res, v14, p8010, doi 10.1158/1078-0432.ccr-08-1208 | 81 | 803 | 2 |
| 29674 | shah sp, 2012, nature, v486, p395, doi 10.1038/nature10933 | 82 | 694 | 3 |
| 30318 | silver dp, 2010, j clin oncol, v28, p1145, doi 10.1200/jco.2009.22.4725 | 135 | 1445 | 2 |
| 30502 | sirohi b, 2008, ann oncol, v19, p1847, doi 10.1093/annonc/mdn395 | 60 | 942 | 2 |
| 30967 | sorlie t, 2001, p natl acad sci usa, v98, p10869, doi 10.1073/pnas.191367098 | 378 | 3706 | 1 |
| 30968 | sorlie t, 2003, p natl acad sci usa, v100, p8418, doi 10.1073/pnas.0932692100 | 257 | 2774 | 1 |
| 30997 | sotiriou c, 2003, p natl acad sci usa, v100, p10393, doi 10.1073/pnas.1732912100 | 84 | 1038 | 1 |
| 32239 | tan dsp, 2008, breast cancer res tr, v111, p27, doi 10.1007/s10549-007-9756-8 | 70 | 995 | 1 |
| 32954 | tischkowitz m, 2007, bmc cancer, v7, doi 10.1186/1471-2407-7-134 | 104 | 1334 | 1 |
| 33476 | turner n, 2004, nat rev cancer, v4, p814, doi 10.1038/nrc1452 | 131 | 1646 | 2 |
| 33487 | turner nc, 2007, oncogene, v26, p2126, doi 10.1038/sj.onc.1210014 | 77 | 1226 | 2 |
| 33517 | tutt a, 2010, lancet, v376, p235, doi 10.1016/s0140-6736(10)60892-6 | 85 | 1077 | 2 |
| 35850 | wolff ac, 2007, j clin oncol, v25, p118, doi 10.1200/jco.2006.09.2775 | 79 | 721 | 3 |

Supplemental Table 2 Details of Group Items by Cluster in VOSviewer

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| id | label | Weight<Occurrences> | Weight<Co-occurrences> | cluster | Score<Avg. pub. year> |
| 1 | ability | 92 | 2543 | 1 | 2013.348 |
| 2 | accumulation | 56 | 1456 | 1 | 2013.196 |
| 3 | action | 56 | 1577 | 1 | 2013.321 |
| 4 | activation | 253 | 7223 | 1 | 2013.557 |
| 5 | activity | 345 | 9675 | 1 | 2013.125 |
| 6 | adjuvant chemotherapy | 135 | 3203 | 2 | 2012.563 |
| 7 | administration | 49 | 1388 | 1 | 2013.551 |
| 8 | adp ribose | 62 | 1603 | 3 | 2011.823 |
| 9 | aezs | 31 | 1078 | 1 | 2013.548 |
| 10 | african american | 35 | 912 | 2 | 2012.171 |
| 11 | african american woman | 29 | 471 | 2 | 2011.69 |
| 12 | age | 331 | 9260 | 4 | 2011.77 |
| 13 | aggressive breast cancer subtype | 20 | 460 | 1 | 2014.45 |
| 14 | aggressive form | 26 | 595 | 1 | 2013.692 |
| 15 | akt | 89 | 2332 | 1 | 2013.337 |
| 16 | aldh1 | 31 | 478 | 2 | 2013.194 |
| 17 | alpha | 143 | 3637 | 1 | 2013.441 |
| 18 | angiogenesis | 64 | 1495 | 1 | 2012.703 |
| 19 | anthracycline | 141 | 3519 | 2 | 2012.376 |
| 20 | anti | 35 | 881 | 1 | 2012.829 |
| 21 | antibody | 114 | 2576 | 1 | 2012.737 |
| 22 | antigen | 39 | 625 | 2 | 2012.872 |
| 23 | antitumor activity | 47 | 1578 | 1 | 2012.957 |
| 24 | apoptosis | 334 | 9577 | 1 | 2013.374 |
| 25 | ar expression | 28 | 542 | 2 | 2013.929 |
| 26 | assay | 137 | 4093 | 1 | 2013.131 |
| 27 | association | 309 | 7341 | 2 | 2012.651 |
| 28 | auc | 31 | 912 | 3 | 2013.774 |
| 29 | author | 27 | 723 | 2 | 2011.667 |
| 30 | autophagy | 63 | 1851 | 1 | 2013.778 |
| 31 | basal marker | 40 | 786 | 2 | 2010.125 |
| 32 | baseline | 27 | 779 | 3 | 2012.63 |
| 33 | bcs | 29 | 618 | 2 | 2011.517 |
| 34 | bcss | 33 | 837 | 2 | 2013.061 |
| 35 | bct | 53 | 1462 | 2 | 2012.434 |
| 36 | beta | 60 | 1688 | 1 | 2014.2 |
| 37 | beta catenin | 43 | 1001 | 1 | 2013.302 |
| 38 | bevacizumab | 98 | 2792 | 3 | 2013.459 |
| 39 | bmi | 74 | 1949 | 2 | 2012.77 |
| 40 | body mass index | 38 | 1117 | 2 | 2012.132 |
| 41 | brain metastase | 64 | 1402 | 2 | 2010.906 |
| 42 | brca mutation | 66 | 1850 | 4 | 2012.258 |
| 43 | brca1 | 772 | 20181 | 4 | 2011.882 |
| 44 | brca1 carrier | 29 | 1087 | 4 | 2011.655 |
| 45 | brca1 mutation | 111 | 3112 | 4 | 2011.766 |
| 46 | brca1 mutation carrier | 80 | 2055 | 4 | 2011.225 |
| 47 | brca2 | 133 | 4149 | 4 | 2011.639 |
| 48 | brca2 carrier | 28 | 1068 | 4 | 2010.357 |
| 49 | brca2 mutation | 94 | 3196 | 4 | 2011.511 |
| 50 | brca2 mutation carrier | 92 | 2948 | 4 | 2010.87 |
| 51 | brcaness | 27 | 572 | 2 | 2013.778 |
| 52 | breast | 130 | 3425 | 4 | 2012.669 |
| 53 | breast cancer cell | 158 | 4317 | 1 | 2013.544 |
| 54 | breast cancer cell line | 131 | 3377 | 1 | 2013.092 |
| 55 | breast cancer risk | 131 | 3997 | 4 | 2011.023 |
| 56 | c myc | 26 | 560 | 1 | 2014 |
| 57 | cancer cell | 101 | 2592 | 1 | 2013.663 |
| 58 | capecitabine | 47 | 1415 | 3 | 2012.766 |
| 59 | carboplatin | 121 | 4496 | 3 | 2013.843 |
| 60 | carrier | 96 | 3283 | 4 | 2011.188 |
| 61 | case control study | 27 | 878 | 4 | 2011.741 |
| 62 | caspase | 60 | 1833 | 1 | 2013.45 |
| 63 | cbc | 29 | 1444 | 4 | 2012.31 |
| 64 | cd44 | 64 | 1337 | 1 | 2012.969 |
| 65 | cddp | 25 | 934 | 1 | 2011.68 |
| 66 | cell | 1254 | 31157 | 1 | 2013.53 |
| 67 | cell cycle | 42 | 1163 | 1 | 2013.381 |
| 68 | cell cycle progression | 29 | 913 | 1 | 2013.31 |
| 69 | cell death | 68 | 2028 | 1 | 2013.397 |
| 70 | cell growth | 75 | 2103 | 1 | 2013.36 |
| 71 | cell line | 294 | 7387 | 1 | 2013.092 |
| 72 | cell migration | 68 | 1937 | 1 | 2013.868 |
| 73 | cell proliferation | 153 | 4218 | 1 | 2013.34 |
| 74 | cell survival | 32 | 1055 | 1 | 2013.031 |
| 75 | cell viability | 60 | 1977 | 1 | 2013.883 |
| 76 | cetuximab | 68 | 2278 | 3 | 2012.235 |
| 77 | cisplatin | 115 | 4015 | 3 | 2013.087 |
| 78 | ck14 | 28 | 542 | 2 | 2011.286 |
| 79 | claudin | 69 | 1090 | 2 | 2013.594 |
| 80 | clinical characteristic | 25 | 461 | 2 | 2012.12 |
| 81 | clinical feature | 31 | 682 | 2 | 2011.774 |
| 82 | clinical significance | 25 | 553 | 2 | 2012.88 |
| 83 | clinicopathological characteristic | 28 | 558 | 2 | 2012.143 |
| 84 | clinicopathological feature | 28 | 489 | 2 | 2012.75 |
| 85 | combination | 359 | 10719 | 3 | 2013.281 |
| 86 | combination therapy | 50 | 1488 | 3 | 2013.2 |
| 87 | combination treatment | 24 | 823 | 1 | 2012.833 |
| 88 | compound | 94 | 2165 | 1 | 2013.787 |
| 89 | concentration | 62 | 1800 | 1 | 2013.79 |
| 90 | confidence interval | 128 | 3717 | 2 | 2012.266 |
| 91 | contralateral breast cancer | 32 | 1296 | 4 | 2012.125 |
| 92 | cox proportional hazards model | 31 | 935 | 2 | 2012.258 |
| 93 | ctc | 59 | 1293 | 3 | 2014.017 |
| 94 | curcumin | 35 | 894 | 1 | 2012.971 |
| 95 | curve | 37 | 1136 | 3 | 2013.189 |
| 96 | cycle | 103 | 3533 | 3 | 2012.903 |
| 97 | cyclophosphamide | 61 | 1716 | 3 | 2012.41 |
| 98 | cytokeratin | 75 | 1434 | 2 | 2011.28 |
| 99 | cytoplasm | 21 | 511 | 1 | 2013.714 |
| 100 | cytotoxicity | 64 | 1836 | 1 | 2013.797 |
| 101 | dasatinib | 33 | 809 | 1 | 2010.818 |
| 102 | date | 40 | 987 | 4 | 2013.25 |
| 103 | day | 181 | 5783 | 3 | 2013.387 |
| 104 | dcis | 37 | 871 | 2 | 2013.216 |
| 105 | december | 45 | 1169 | 2 | 2012.378 |
| 106 | decrease | 55 | 1509 | 1 | 2013.4 |
| 107 | degradation | 44 | 1134 | 1 | 2013.523 |
| 108 | deleterious mutation | 27 | 910 | 4 | 2011.556 |
| 109 | depletion | 42 | 1128 | 1 | 2013.691 |
| 110 | dfs | 162 | 3614 | 2 | 2013.068 |
| 111 | diagnosis | 279 | 7099 | 2 | 2012.434 |
| 112 | difference | 182 | 4062 | 2 | 2012.275 |
| 113 | disease free survival | 161 | 3634 | 2 | 2012.497 |
| 114 | disease progression | 29 | 775 | 3 | 2013.345 |
| 115 | distant metastase | 36 | 908 | 2 | 2011.75 |
| 116 | distant recurrence | 41 | 1055 | 2 | 2012.244 |
| 117 | dna damage | 63 | 1716 | 1 | 2013.079 |
| 118 | docetaxel | 75 | 2107 | 3 | 2012.6 |
| 119 | dose | 118 | 4183 | 3 | 2013.348 |
| 120 | downregulation | 58 | 1822 | 1 | 2013.31 |
| 121 | doxorubicin | 75 | 1952 | 1 | 2012.813 |
| 122 | drug | 205 | 5120 | 1 | 2013.381 |
| 123 | drug resistance | 45 | 1122 | 1 | 2013.711 |
| 124 | ductal carcinoma | 29 | 627 | 2 | 2012.621 |
| 125 | e cadherin | 74 | 1547 | 2 | 2012.595 |
| 126 | e cadherin expression | 27 | 553 | 2 | 2012.519 |
| 127 | early onset breast cancer | 24 | 658 | 4 | 2011 |
| 128 | effect | 721 | 21028 | 1 | 2013.322 |
| 129 | effective targeted therapy | 28 | 491 | 1 | 2013.321 |
| 130 | efficacy | 238 | 6848 | 3 | 2013.37 |
| 131 | egfr inhibitor | 25 | 804 | 1 | 2012.36 |
| 132 | emt | 98 | 2497 | 1 | 2013.755 |
| 133 | epirubicin | 28 | 863 | 3 | 2012.464 |
| 134 | epithelial | 44 | 1140 | 1 | 2013.614 |
| 135 | epithelial mesenchymal transition | 43 | 1068 | 1 | 2013.861 |
| 136 | er alpha | 46 | 1188 | 1 | 2013.457 |
| 137 | er beta | 53 | 1235 | 1 | 2014.283 |
| 138 | erk | 43 | 1168 | 1 | 2013.488 |
| 139 | event | 114 | 3553 | 3 | 2013.018 |
| 140 | exon | 61 | 1298 | 4 | 2012.164 |
| 141 | exposure | 60 | 1840 | 1 | 2013.05 |
| 142 | family | 88 | 2349 | 4 | 2012.648 |
| 143 | family history | 112 | 3534 | 4 | 2012.429 |
| 144 | fgfr2 | 20 | 353 | 4 | 2011.5 |
| 145 | first time | 23 | 575 | 1 | 2013.217 |
| 146 | flow cytometry | 36 | 1184 | 1 | 2013.583 |
| 147 | fluorouracil | 30 | 812 | 3 | 2012.4 |
| 148 | formation | 93 | 2374 | 1 | 2013.247 |
| 149 | free survival | 117 | 2747 | 2 | 2012.282 |
| 150 | frequency | 121 | 2790 | 4 | 2012.422 |
| 151 | gefitinib | 38 | 1412 | 1 | 2013.5 |
| 152 | gemcitabine | 68 | 2810 | 3 | 2013.412 |
| 153 | germline mutation | 79 | 2032 | 4 | 2012.329 |
| 154 | glv | 28 | 572 | 1 | 2013.607 |
| 155 | grade | 266 | 7315 | 3 | 2012.568 |
| 156 | growth | 230 | 6302 | 1 | 2013.113 |
| 157 | hazard ratio | 120 | 3478 | 2 | 2012.567 |
| 158 | hcc | 30 | 1034 | 1 | 2013.4 |
| 159 | hif | 66 | 2009 | 1 | 2013.758 |
| 160 | high ki | 21 | 486 | 2 | 2013.143 |
| 161 | high risk | 37 | 917 | 4 | 2012.405 |
| 162 | higher level | 25 | 551 | 1 | 2013.08 |
| 163 | higher risk | 30 | 695 | 2 | 2012.367 |
| 164 | histological grade | 52 | 895 | 2 | 2012 |
| 165 | hospital | 56 | 1324 | 2 | 2012.143 |
| 166 | human breast cancer | 46 | 1167 | 1 | 2012 |
| 167 | human breast cancer cell | 30 | 907 | 1 | 2012.733 |
| 168 | human tnbc | 23 | 501 | 1 | 2013.652 |
| 169 | hypoxia | 45 | 1409 | 1 | 2013.089 |
| 170 | igf | 41 | 1098 | 1 | 2012.683 |
| 171 | immunohistochemical staining | 51 | 1005 | 2 | 2012.49 |
| 172 | inactivation | 35 | 865 | 1 | 2012.971 |
| 173 | independent predictor | 49 | 1237 | 2 | 2012.612 |
| 174 | independent prognostic factor | 67 | 1323 | 2 | 2012.687 |
| 175 | individual | 44 | 1023 | 4 | 2011.432 |
| 176 | induction | 93 | 2830 | 1 | 2013.344 |
| 177 | information | 101 | 2201 | 2 | 2012.753 |
| 178 | inhibition | 364 | 10467 | 1 | 2013.209 |
| 179 | inhibitor | 404 | 10898 | 1 | 2012.993 |
| 180 | iniparib | 41 | 1428 | 3 | 2012.488 |
| 181 | insulin | 31 | 783 | 1 | 2013.516 |
| 182 | interaction | 88 | 2277 | 1 | 2013.443 |
| 183 | invasion | 268 | 6457 | 1 | 2013.481 |
| 184 | invasive breast cancer | 85 | 2062 | 2 | 2011.906 |
| 185 | invasive ductal carcinoma | 44 | 813 | 2 | 2011.773 |
| 186 | invasiveness | 32 | 756 | 1 | 2013.406 |
| 187 | ixabepilone | 25 | 776 | 3 | 2012.28 |
| 188 | january | 68 | 1652 | 2 | 2012.309 |
| 189 | kaplan meier method | 31 | 843 | 2 | 2012.742 |
| 190 | kinase | 217 | 6020 | 1 | 2013.111 |
| 191 | knockdown | 92 | 2506 | 1 | 2013.38 |
| 192 | lapatinib | 41 | 1168 | 1 | 2013.073 |
| 193 | locoregional recurrence | 24 | 716 | 2 | 2011.875 |
| 194 | loh | 26 | 460 | 4 | 2012.115 |
| 195 | lrr | 39 | 1286 | 2 | 2012.18 |
| 196 | luminal a | 28 | 520 | 2 | 2012.107 |
| 197 | luminal b | 22 | 394 | 2 | 2012.818 |
| 198 | lymph node | 81 | 1991 | 2 | 2012.556 |
| 199 | lymph node status | 29 | 722 | 2 | 2012.448 |
| 200 | lymphovascular invasion | 21 | 582 | 2 | 2012.048 |
| 201 | mammography | 40 | 621 | 2 | 2011.6 |
| 202 | mapk | 32 | 984 | 1 | 2012.875 |
| 203 | margin | 60 | 1066 | 2 | 2012.333 |
| 204 | mastectomy | 138 | 4159 | 2 | 2012.406 |
| 205 | mbc | 43 | 1052 | 2 | 2012.721 |
| 206 | mcf | 79 | 2623 | 1 | 2013.253 |
| 207 | mcl | 23 | 528 | 1 | 2014.783 |
| 208 | mda mb | 535 | 16703 | 1 | 2013.497 |
| 209 | mean age | 21 | 459 | 2 | 2012.667 |
| 210 | mechanism | 249 | 6722 | 1 | 2013.333 |
| 211 | median | 127 | 3838 | 2 | 2012.221 |
| 212 | median age | 55 | 1765 | 2 | 2012.6 |
| 213 | menopausal status | 29 | 727 | 2 | 2012.172 |
| 214 | met | 59 | 1708 | 1 | 2013.525 |
| 215 | metaplastic carcinoma | 20 | 310 | 2 | 2013.4 |
| 216 | metastasis | 507 | 11476 | 1 | 2013.168 |
| 217 | metastatic breast cancer | 74 | 2140 | 3 | 2012.257 |
| 218 | metastatic tnbc | 54 | 1307 | 3 | 2013.019 |
| 219 | metastatic triple negative breast cancer | 97 | 3095 | 3 | 2013.402 |
| 220 | metformin | 51 | 1542 | 1 | 2012.314 |
| 221 | methods | 24 | 651 | 2 | 2012.458 |
| 222 | mg kg | 35 | 1177 | 3 | 2013.457 |
| 223 | mg m | 80 | 3128 | 3 | 2013.138 |
| 224 | microrna | 72 | 1816 | 1 | 2013.764 |
| 225 | migration | 145 | 4029 | 1 | 2013.91 |
| 226 | mir | 440 | 9215 | 1 | 2013.957 |
| 227 | mirna | 124 | 2798 | 1 | 2014.202 |
| 228 | mmp | 64 | 1505 | 1 | 2013.563 |
| 229 | molecular mechanism | 40 | 1004 | 1 | 2013.325 |
| 230 | month | 363 | 9998 | 3 | 2012.444 |
| 231 | mouse | 176 | 4836 | 1 | 2013.114 |
| 232 | mri | 67 | 1333 | 2 | 2012.746 |
| 233 | mrna | 65 | 1739 | 1 | 2013.446 |
| 234 | mtnbc | 31 | 968 | 3 | 2014.194 |
| 235 | mtor | 39 | 1091 | 1 | 2013.564 |
| 236 | mu m | 47 | 1345 | 1 | 2013.234 |
| 237 | multivariate analysis | 122 | 2974 | 2 | 2012.164 |
| 238 | mutation | 587 | 12956 | 4 | 2012.47 |
| 239 | mutation carrier | 116 | 3869 | 4 | 2011.345 |
| 240 | mutation status | 58 | 1716 | 4 | 2012.276 |
| 241 | nac | 140 | 3064 | 2 | 2013.621 |
| 242 | nanoparticle | 58 | 1231 | 1 | 2014.466 |
| 243 | neoadjuvant chemotherapy | 175 | 4162 | 2 | 2012.857 |
| 244 | neutropenia | 39 | 1596 | 3 | 2013.487 |
| 245 | nodal status | 52 | 1342 | 2 | 2012.115 |
| 246 | non basal | 26 | 537 | 2 | 2011.654 |
| 247 | non carrier | 41 | 1595 | 4 | 2011.512 |
| 248 | non tnbc patient | 35 | 598 | 2 | 2012.914 |
| 249 | noncarrier | 23 | 871 | 4 | 2011.348 |
| 250 | none | 33 | 881 | 4 | 2011.758 |
| 251 | normal breast tissue | 22 | 381 | 1 | 2013.182 |
| 252 | normal tissue | 34 | 750 | 1 | 2013.706 |
| 253 | notch | 30 | 670 | 1 | 2013.067 |
| 254 | novel | 35 | 822 | 1 | 2013.171 |
| 255 | novel therapeutic target | 25 | 434 | 1 | 2013.2 |
| 256 | nude mouse | 48 | 1661 | 1 | 2012.313 |
| 257 | ny eso | 39 | 479 | 2 | 2012.821 |
| 258 | obesity | 43 | 986 | 2 | 2012.605 |
| 259 | odds ratio | 50 | 1544 | 4 | 2011.86 |
| 260 | olaparib | 37 | 1476 | 3 | 2013.378 |
| 261 | orr | 36 | 1396 | 3 | 2013.083 |
| 262 | ovarian cancer | 32 | 956 | 4 | 2012.469 |
| 263 | overall response rate | 20 | 671 | 3 | 2012.9 |
| 264 | overall survival | 342 | 8399 | 2 | 2012.646 |
| 265 | p0001 | 51 | 1110 | 2 | 2013.51 |
| 266 | p21 | 22 | 665 | 1 | 2013.091 |
| 267 | p27 | 23 | 648 | 1 | 2014.087 |
| 268 | paclitaxel | 143 | 4845 | 3 | 2013.399 |
| 269 | pakt | 26 | 626 | 1 | 2013.462 |
| 270 | palb2 | 23 | 513 | 4 | 2013.565 |
| 271 | parameter | 103 | 2348 | 2 | 2012.932 |
| 272 | parp | 81 | 2233 | 3 | 2012.321 |
| 273 | parp inhibitor | 60 | 1774 | 3 | 2012.083 |
| 274 | partial response | 22 | 659 | 3 | 2012.864 |
| 275 | pathologic complete response | 47 | 1340 | 2 | 2012.787 |
| 276 | pathological complete response | 44 | 1277 | 3 | 2013.455 |
| 277 | pathway | 469 | 11650 | 1 | 2013.35 |
| 278 | patients | 45 | 1114 | 2 | 2012.556 |
| 279 | pcr | 265 | 6647 | 2 | 2013.068 |
| 280 | pcr rate | 80 | 2192 | 2 | 2013.238 |
| 281 | pfs | 56 | 1838 | 3 | 2013.161 |
| 282 | pgr | 63 | 1356 | 2 | 2011.27 |
| 283 | phase | 67 | 2298 | 3 | 2013.373 |
| 284 | phosphorylation | 97 | 2751 | 1 | 2013.32 |
| 285 | pi3k | 42 | 1447 | 1 | 2013.905 |
| 286 | platinum | 102 | 1834 | 3 | 2013.118 |
| 287 | poly | 84 | 1999 | 3 | 2012.191 |
| 288 | polymerase | 52 | 1358 | 3 | 2012.154 |
| 289 | polymorphism | 100 | 2097 | 4 | 2012.22 |
| 290 | population | 289 | 7320 | 4 | 2012.242 |
| 291 | positivity | 80 | 1607 | 2 | 2012.9 |
| 292 | potential | 118 | 3114 | 1 | 2013.593 |
| 293 | potential target | 28 | 660 | 1 | 2013.321 |
| 294 | potential therapeutic target | 48 | 1036 | 1 | 2013.021 |
| 295 | predictor | 97 | 2378 | 2 | 2012.68 |
| 296 | prevalence | 122 | 3042 | 4 | 2012.697 |
| 297 | primary end point | 23 | 845 | 3 | 2012.957 |
| 298 | primary endpoint | 22 | 892 | 3 | 2012.909 |
| 299 | process | 71 | 1899 | 1 | 2013.535 |
| 300 | prognostic factor | 143 | 3265 | 2 | 2012.748 |
| 301 | prognostic impact | 34 | 779 | 2 | 2012.088 |
| 302 | prognostic significance | 50 | 1168 | 2 | 2012 |
| 303 | progression free survival | 74 | 2432 | 3 | 2013.054 |
| 304 | proliferation | 223 | 5790 | 1 | 2013.336 |
| 305 | prospective study | 28 | 659 | 2 | 2012.214 |
| 306 | protein level | 46 | 1168 | 1 | 2013.522 |
| 307 | pten | 46 | 1242 | 1 | 2013.739 |
| 308 | pten loss | 22 | 541 | 1 | 2013.682 |
| 309 | race | 53 | 1520 | 2 | 2011.302 |
| 310 | radiotherapy | 89 | 2514 | 2 | 2013.506 |
| 311 | range | 114 | 3184 | 2 | 2012.614 |
| 312 | rank test | 39 | 958 | 2 | 2012.051 |
| 313 | rap | 25 | 575 | 1 | 2014 |
| 314 | rapamycin | 39 | 1390 | 1 | 2012.18 |
| 315 | rate | 418 | 11038 | 2 | 2012.352 |
| 316 | receptor | 1489 | 30487 | 2 | 2012.254 |
| 317 | recurrence | 280 | 6766 | 2 | 2012.307 |
| 318 | regimen | 141 | 3712 | 3 | 2013.135 |
| 319 | regulation | 144 | 3767 | 1 | 2013.708 |
| 320 | residual disease | 25 | 613 | 2 | 2012.92 |
| 321 | residual tumor | 23 | 669 | 2 | 2013.217 |
| 322 | resistance | 155 | 3894 | 1 | 2013.452 |
| 323 | response rate | 74 | 2182 | 3 | 2012.689 |
| 324 | retrospective study | 33 | 773 | 2 | 2012.606 |
| 325 | rfs | 59 | 1417 | 2 | 2012.356 |
| 326 | risk | 513 | 14436 | 4 | 2012 |
| 327 | risk factor | 97 | 2327 | 2 | 2012.289 |
| 328 | safety | 49 | 1794 | 3 | 2013.51 |
| 329 | significant association | 45 | 1157 | 2 | 2012.889 |
| 330 | significant difference | 80 | 1831 | 2 | 2012.488 |
| 331 | silencing | 56 | 1464 | 1 | 2013.625 |
| 332 | single agent | 32 | 1039 | 1 | 2012.094 |
| 333 | sirna | 79 | 2223 | 1 | 2013.57 |
| 334 | snp | 50 | 1554 | 4 | 2011.52 |
| 335 | sporadic breast cancer | 24 | 597 | 4 | 2011.208 |
| 336 | src | 34 | 806 | 1 | 2012.471 |
| 337 | stage | 309 | 7396 | 2 | 2012.774 |
| 338 | stroma | 36 | 450 | 2 | 2012.75 |
| 339 | sunitinib | 23 | 755 | 3 | 2013.739 |
| 340 | suppression | 65 | 1713 | 1 | 2013.677 |
| 341 | surgery | 150 | 3850 | 2 | 2012.347 |
| 342 | survival outcome | 49 | 1166 | 2 | 2012.49 |
| 343 | survival rate | 80 | 2117 | 2 | 2012.5 |
| 344 | suvmax | 44 | 739 | 2 | 2013.659 |
| 345 | target | 286 | 6423 | 1 | 2013.154 |
| 346 | taxane | 96 | 2617 | 3 | 2012.667 |
| 347 | tgf beta | 51 | 1345 | 1 | 2013.98 |
| 348 | therapeutic target | 134 | 2594 | 1 | 2013.209 |
| 349 | til | 29 | 753 | 2 | 2013.966 |
| 350 | tn breast cancer | 112 | 2498 | 2 | 2011.134 |
| 351 | tn patient | 31 | 713 | 2 | 2010.774 |
| 352 | tn tumor | 56 | 1125 | 2 | 2011.839 |
| 353 | tnbc cell | 348 | 9874 | 1 | 2014.046 |
| 354 | tnbc cell line | 174 | 4733 | 1 | 2013.615 |
| 355 | tnbc group | 34 | 789 | 2 | 2013.353 |
| 356 | tnbc tissue | 36 | 857 | 1 | 2014.222 |
| 357 | tnbc tumor | 38 | 878 | 1 | 2014.158 |
| 358 | total | 133 | 3490 | 2 | 2012.534 |
| 359 | toxicity | 137 | 4316 | 3 | 2013.416 |
| 360 | tp53 | 26 | 722 | 4 | 2012.462 |
| 361 | trail | 44 | 1226 | 1 | 2012.659 |
| 362 | transition | 44 | 1197 | 1 | 2013.591 |
| 363 | trend | 62 | 1807 | 4 | 2011.516 |
| 364 | trial | 280 | 7220 | 3 | 2012.5 |
| 365 | triple | 38 | 767 | 2 | 2011.368 |
| 366 | triple negative breast cancer cell | 187 | 5340 | 1 | 2013.562 |
| 367 | triple negative breast cancer cell line | 52 | 1493 | 1 | 2013.077 |
| 368 | triple negative breast cancer cells | 41 | 1064 | 1 | 2013.366 |
| 369 | triple negative breast carcinoma | 25 | 509 | 2 | 2012.24 |
| 370 | triple negative cancer | 42 | 577 | 2 | 2011.976 |
| 371 | triple negative mda mb | 28 | 984 | 1 | 2013.143 |
| 372 | triple negative patient | 37 | 846 | 3 | 2010.946 |
| 373 | triple negative phenotype | 67 | 1243 | 2 | 2010.433 |
| 374 | triple negative subtype | 29 | 674 | 2 | 2012.586 |
| 375 | tumor characteristic | 37 | 831 | 2 | 2012.27 |
| 376 | tumor grade | 44 | 899 | 2 | 2012.705 |
| 377 | tumor growth | 135 | 3505 | 1 | 2013.607 |
| 378 | tumor size | 161 | 3756 | 2 | 2012.242 |
| 379 | tumor suppressor | 32 | 765 | 1 | 2013.906 |
| 380 | tumor tissue | 45 | 1123 | 1 | 2013.711 |
| 381 | tumorigenesis | 42 | 1152 | 1 | 2013.119 |
| 382 | univariate analysis | 30 | 696 | 2 | 2012 |
| 383 | upregulation | 36 | 957 | 1 | 2013.583 |
| 384 | variant | 109 | 2779 | 4 | 2011.982 |
| 385 | variety | 26 | 566 | 1 | 2012.923 |
| 386 | viability | 32 | 1070 | 1 | 2013.938 |
| 387 | vimentin | 29 | 737 | 1 | 2013.069 |
| 388 | vitro | 228 | 6548 | 1 | 2013.364 |
| 389 | vivo | 112 | 3153 | 1 | 2013.348 |
| 390 | week | 113 | 3856 | 3 | 2012.938 |
| 391 | western blot | 30 | 1049 | 1 | 2013.3 |
| 392 | western blot analysis | 22 | 672 | 1 | 2013.546 |
| 393 | western blotting | 30 | 1013 | 1 | 2013.733 |
| 394 | woman | 864 | 22424 | 4 | 2011.947 |
| 395 | women | 36 | 1064 | 2 | 2011.75 |
| 396 | xenograft | 98 | 2763 | 1 | 2013.276 |
| 397 | xenograft model | 61 | 1727 | 1 | 2013.443 |
| 398 | year | 541 | 14945 | 2 | 2012.052 |
| 399 | young woman | 32 | 1019 | 4 | 2011.625 |
| 400 | younger age | 40 | 1024 | 2 | 2012.45 |